文献速递神经肿瘤

成人罕见脑肿瘤手术后短期转归:瑞典全国登记研究及与SEER数据库比较

Short-term outcome following surgery for rare brain tumor entities in adults: a Swedish nation-wide registry-based study and comparison with SEER database.
PubMed 文献 · J Neurooncol · 2020-05-19

基于瑞典脑肿瘤登记(SBTR)纳入2009–2015年诊断的216例成人罕见脑肿瘤(室管膜瘤、室管膜下瘤、神经节胶质瘤、毛细胞星形细胞瘤、原始神经外胚层肿瘤),分析症状、肿瘤特征和手术转归,并在SEER登记中验证。研究报告了各亚型年龄、症状分布、全切除比例、新发神经功能缺损、术后并发症及30天和1年死亡率等基准数据,旨在辅助临床决策和患者咨询。

要点

  • 多数肿瘤类别全切除率>50%,新发神经功能缺损发生率为11.1–34.4%。
  • 术后30天内死亡3例,1年死亡率为0–14.3%。
  • 神经节胶质瘤患者中64.2%以癫痫起病,局灶性缺损为最常见症状(39.6–71.4%)。

核心结论

  • 瑞典脑肿瘤登记提供了成人罕见脑肿瘤手术后症状、肿瘤特征和转归的基准数据,并在独立登记中验证。

研究设计与样本

  • 基于瑞典脑肿瘤登记(SBTR)的全国性登记研究,纳入2009–2015年诊断的216例成人罕见脑肿瘤患者,并在SEER登记中验证。

主要发现

  • 各亚型平均年龄:神经节胶质瘤38.3±17.2岁,毛细胞星形细胞瘤36.2±16.9岁,原始神经外胚层肿瘤37.0±19.1岁,室管膜瘤51.7±16.3岁,室管膜下瘤49.8±14.3岁。
  • 最常见症状为局灶性缺损(39.6–71.4%),神经节胶质瘤患者中64.2%以癫痫起病。
  • 多数患者术前体能状态为0–1,但原始神经外胚层肿瘤患者中高达15.0%体能状态为4。
  • 多数肿瘤类别全切除率>50%;新发神经功能缺损发生率为11.1–34.4%。
  • 术后并发症:任何类型血肿0–4.8%,感染1.9–15.6%,静脉血栓栓塞0–7.8%,需再次手术的并发症3.7–10.9%;30天内死亡3例,1年死亡率0–14.3%。

临床怎么用

  • 研究结果可为成人罕见脑肿瘤的临床决策和患者咨询提供基准参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate outcomes after surgery for rare brain tumors using the Swedish Brain Tumor Registry (SBTR). METHODS: This is a nationwide study of patient in the SBTR, validated in the Surveillance, Epidemiology, and End Results (SEER) registries. We included all adults diagnosed 2009-2015 with a rare brain tumor entity (n = 216), defined as ependymoma (EP, n = 64), subependymoma (SUBEP, n = 21), ganglioglioma (GGL, n = 54), pilocytic astrocytoma (PA, n = 56) and primitive neuroectodermal tumor (PNET, n = 21). We analyzed symptomatology, tumor characteristics and outcomes. RESULTS: Mean age was 38.3 ± 17.2 years in GGL, 36.2 ± 16.9 in PA, 37.0 ± 19.1 in PNET, 51.7 ± 16.3 in EP and 49.8 ± 14.3 in SUBEP. The most common symptom was focal deficit (39.6-71.4%), and this symptom was most common in GGL patients with 64.2% of GGL presenting with seizures. Most patients had no or little restriction in activity before surgery (Performance Status 0-1), although up to 15.0% of PNET patients had a performance status of 4. Gross total resection was achieved in most (> 50%) tumor categories. Incidence of new deficits was 11.1-34.4%. In terms of postoperative complications, 0-4.8% had a hematoma of any kind, 1.9-15.6% an infection, 0-7.8% a venous thromboembolism and 3.7-10.9% experienced a complication requiring reoperation. There were 3 deaths within 30-days of surgery, and a 1-year mortality of 0-14.3%. CONCLUSION: We have provided benchmarks for the current symptomatology, tumor characteristics and outcomes after surgery for rare brain tumors as collected by the SBTR and validated our results in an independent registry. These results may aid in clinical decision making and advising patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Bartek J, Dhawan S, Thurin E, et al. Short-term outcome following surgery for rare brain tumor entities in adults: a Swedish nation-wide registry-based study and comparison with SEER database. J Neurooncol. 2020. PMID: 32424575. doi:10.1007/s11060-020-03490-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。